PSA in the New Millennium: A Powerful Predictor of Prostate Cancer Prognosis and Radical Prostatectomy Outcomes - Results from the SEARCH Database

European Urology

Volumn 53, Issue 4, 2008, Pages 758-766

  Freedland, Stephen J ^a,b,c   Hotaling, James M ^b   Fitzsimons, Nicholas J ^b   Presti Jr , Joseph C ^d,e   Kane, Christopher J ^f,g   Terris, Martha K ^h,i   Aronson, William J ^j,k   Amling, Christopher L ^l  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Palo Alto Veteran Affairs Medical Center   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

^j VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Alabama   (United States)

more..

Author keywords

Biochemical recurrence; Prostate cancer; PSA; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 39449121966     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.047     Document Type: Article

References (26)

1. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973-1995; SEER program, National Cancer Institute NIH publication no. 99-4543. Bethesda, MD: 1999.
2. Vutuc C., Waldhoer T., Sevelda P., Micksche M., and Haidinger G. Self-reported prostate cancer screening in Austria. J Med Screen 13 (2006) 148-151
3. Luján M., Páez A., Pascual C., Angulo J., Miravalles E., and Berenguer A. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 50 (2006) 1234-1240 discussion 1239-40
4. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
5. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the united states is over for prostate cancer: What happened in the last 20 years?. J Urol 172 (2004) 1297-1301
6. Freedland S.J., Aronson W.J., Kane C.J., et al. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 101 (2004) 748-753
7. Freedland S.J., Mangold L.A., Walsh P.C., and Partin A.W. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 174 (2005) 1276-1281
8. Antenor J.A., Roehl K.A., Eggener S.E., Kundu S.D., Han M., and Catalona W.J. Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology 66 (2005) 156-160
9. Freedland S.J., Presti Jr. J.C., Amling C.L., et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 61 (2003) 736-741
10. Han M., Partin A.W., Piantadosi S., Epstein J.I., and Walsh P.C. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166 (2001) 416-419
11. Mitchell R.E., Desai M., Shah J.B., Olsson C.A., Benson M.C., and McKiernan J.M. Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. J Urol 175 (2006) 1663-1667 discussion 1667
12. Freedland S.J., Amling C.L., Dorey F., et al. Race as an outcome predictor after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60 (2002) 670-674
13. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61 (2003) 365-369
14. Wang M.C., Valenzuela L.A., Murphy G.P., and Chu T.M. Purification of a human prostate specific antigen. Invest Urol 17 (1979) 159-163
15. Cooner W.H., Mosley B.R., Rutherford Jr. C.L., et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 139 (1988) 758-761
16. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
17. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
18. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
19. Carter H.B. Prostate cancers in men with low PSA levels-must we find them?. N Engl J Med 350 (2004) 2292-2294
20. Chun F.K.-H., Briganti A., Gallina A., et al. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 52 (2007) 1067-1075
21. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., and Partin A.W. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176 (2006) 1404-1408
22. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
23. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253
24. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
25. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
26. Carter H.B., and Isaacs W.B. Improved biomarkers for prostate cancer: A definite need. J Natl Cancer Inst 96 (2004) 813-815